# Waters Corp: overview

WAT · NYSE · CIK 1000697 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/wat.md) · [Financials](/companies/wat/financials.md) · [Filings](/companies/wat/filings.md) · [Insiders](/companies/wat/insiders.md)

Latest reported revenue: [$1.65bn](/filings/0001193125-26-344691.md) for Q2 FY2026, three months to 2026-07-04, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-344691).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [740](/filings/0001193125-25-263533.md) | [873](/filings/0001193125-26-062604.md) | [662](/filings/0001193125-26-219487.md) | [771](/filings/0001193125-26-344691.md) | [800](/filings/0001193125-25-263533.md) | [932](/filings/0001193125-26-062604.md) | [1,267](/filings/0001193125-26-219487.md) | [1,645](/filings/0001193125-26-344691.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [28.5%](/filings/0001193125-25-263533.md) | [33.5%](/filings/0001193125-26-062604.md) | [23.0%](/filings/0001193125-26-219487.md) | [24.4%](/filings/0001193125-26-344691.md) | [24.0%](/filings/0001193125-25-263533.md) | [29.0%](/filings/0001193125-26-062604.md) | [(3.7%)](/filings/0001193125-26-219487.md) | [(5.2%)](/filings/0001193125-26-344691.md) |
| Net margin | % | [21.8%](/filings/0001193125-25-263533.md) | [26.5%](/filings/0001193125-26-062604.md) | [18.3%](/filings/0001193125-26-219487.md) | [19.1%](/filings/0001193125-26-344691.md) | [18.6%](/filings/0001193125-25-263533.md) | [24.2%](/filings/0001193125-26-062604.md) | [(5.7%)](/filings/0001193125-26-219487.md) | [(8.3%)](/filings/0001193125-26-344691.md) |
| Diluted EPS | $ per share | [2.71](/filings/0001193125-25-263533.md) | [3.88](/filings/0001193125-26-062604.md) | [2.03](/filings/0001193125-26-219487.md) | [2.47](/filings/0001193125-26-344691.md) | [2.50](/filings/0001193125-25-263533.md) | [3.77](/filings/0001193125-26-062604.md) | [(0.87)](/filings/0001193125-26-219487.md) | [(1.39)](/filings/0001193125-26-344691.md) |
| Free cash flow | $m | not reported | not reported | [234](/filings/0001193125-26-219487.md) | [18.0 d](/filings/0001193125-26-344691.md) | not reported | not reported | [(42.0)](/filings/0001193125-26-219487.md) | [153 d](/filings/0001193125-26-344691.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Net income: us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,786](/filings/0001193125-24-047491.md) | [2,972](/filings/0001193125-25-034579.md) | [2,956](/filings/0001193125-26-062604.md) | [2,958](/filings/0001193125-26-062604.md) | [3,165](/filings/0001193125-26-062604.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [29.5%](/filings/0001193125-24-047491.md) | [29.4%](/filings/0001193125-25-034579.md) | [27.7%](/filings/0001193125-26-062604.md) | [27.9%](/filings/0001193125-26-062604.md) | [25.4%](/filings/0001193125-26-062604.md) |
| Net margin | % | [24.9%](/filings/0001193125-24-047491.md) | [23.8%](/filings/0001193125-25-034579.md) | [21.7%](/filings/0001193125-26-062604.md) | [21.6%](/filings/0001193125-26-062604.md) | [20.3%](/filings/0001193125-26-062604.md) |
| Diluted EPS | $ per share | [11.17](/filings/0001193125-24-047491.md) | [11.73](/filings/0001193125-25-034579.md) | [10.84](/filings/0001193125-26-062604.md) | [10.71](/filings/0001193125-26-062604.md) | [10.76](/filings/0001193125-26-062604.md) |
| Free cash flow | $m | not reported | not reported | [442](/filings/0001193125-26-062604.md) | [620](/filings/0001193125-26-062604.md) | [540](/filings/0001193125-26-062604.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/wat/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $3.18bn | 8,484,939 |  | Reduced −58,075 |
| [MASSACHUSETTS FINANCIAL SERVICES CO /MA/](/funds/912938.md) | 2026-06-30 | $2.53bn | 4,625,035 |  | Reduced −5,083 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.41bn | 6,415,552 |  | Added +36,777 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.78bn | 4,740,524 |  | Reduced −13,661 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.64bn | 4,382,008 |  | Added +19,998 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $1.31bn | 3,494,267 |  | Added +1,325,982 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $984.8m | 2,636,146 |  | Reduced −10,312 |
| [Fundsmith LLP](/funds/1569205.md) | 2026-06-30 | $852.7m | 2,273,632 |  | Reduced −938,443 |
| [ALLIANCEBERNSTEIN L.P.](/funds/1109448.md) | 2026-06-30 | $802.4m | 2,694,590 |  | Added +577,853 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $796.2m | 2,158,391 |  | Added +184,743 |

## Recent filings

[All 1,364 filings](/companies/wat/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-21 | 13:20 ET | [8-K](/filings/0001193125-26-360081.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events | 0001193125-26-360081 |
| 2026-08-11 | 20:16 ET | [10-Q](/filings/0001193125-26-344691.md) | Quarterly report, period 2026-07-04 | 0001193125-26-344691 |
| 2026-08-04 | 10:10 ET | [8-K](/filings/0001193125-26-331413.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-331413 |
| 2026-05-22 | 20:15 ET | [8-K](/filings/0001193125-26-236929.md) | 5.07 Shareholder vote results | 0001193125-26-236929 |
| 2026-05-12 | 20:16 ET | [10-Q](/filings/0001193125-26-219487.md) | Quarterly report, period 2026-04-04 | 0001193125-26-219487 |
| 2026-05-05 | 10:10 ET | [8-K](/filings/0001193125-26-204955.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-204955 |
| 2026-04-09 | 20:15 ET | [DEF 14A](/filings/0001193125-26-149657.md) | Proxy statement, period 2026-05-21 | 0001193125-26-149657 |
| 2026-03-23 | 20:15 ET | [8-K](/filings/0001193125-26-119753.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-119753 |
| 2026-03-16 | 12:44 ET | [8-K](/filings/0001193125-26-107339.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-107339 |
| 2026-02-23 | 14:10 ET | [10-K](/filings/0001193125-26-062604.md) | Annual report, period 2025-12-31 | 0001193125-26-062604 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-062604.md), filed Feb 23, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1000697
- Tickers: WAT
- Exchange: NYSE
- SIC code: 3826 Laboratory Analytical Instruments
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.